{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:02:54Z","timestamp":1789657374881,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annonc.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:11:19Z","timestamp":1773457879000},"page":"936-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"B.","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-6463","authenticated-orcid":false,"given":"H.","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kostic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-836X","authenticated-orcid":false,"given":"K.S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.W.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4334-4028","authenticated-orcid":false,"given":"M.J.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Milenkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2656-0650","authenticated-orcid":false,"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5588-8332","authenticated-orcid":false,"given":"S.-B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.annonc.2026.03.002_bib1","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2026.03.002_bib2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.annonc.2026.03.002_bib3","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.03.002_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0022-3565(25)38962-7","article-title":"Potential neurotoxicity of the solvent vehicle for cyclosporine","volume":"268","author":"Windebank","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"31","key":"10.1016\/j.annonc.2026.03.002_bib5","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.03.002_bib6","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","article-title":"Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies","volume":"10","author":"Kim","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12 Pt 1","key":"10.1016\/j.annonc.2026.03.002_bib7","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1535-7163.MCT-07-0261","article-title":"Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation","volume":"6","author":"Hong","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.annonc.2026.03.002_bib8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","article-title":"Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.annonc.2026.03.002_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s10637-012-9841-7","article-title":"A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel","volume":"31","author":"Hong","year":"2013","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.annonc.2026.03.002_bib10","doi-asserted-by":"crossref","first-page":"129-e8","DOI":"10.1634\/theoncologist.2016-0273","article-title":"A phase I\/IIa study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors or gastric cancer","volume":"22","author":"Ryu","year":"2017","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.annonc.2026.03.002_bib11","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/annonc\/mdy055","article-title":"Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy","volume":"29","author":"Kang","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.03.002_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211061989","article-title":"Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)","volume":"13","author":"Kim","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2026.03.002_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.304","article-title":"265P Phase II study of DHP107 oral paclitaxel compared to IV paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer (MBC): opera (NCT03326102)","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.03.002_bib14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1040-8428(02)00109-9","article-title":"Weekly administration of paclitaxel: theoretical and clinical basis","volume":"44","author":"Marchetti","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.annonc.2026.03.002_bib15","first-page":"2112","article-title":"Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL","volume":"56","author":"Sparreboom","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.03.002_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114024","article-title":"Paclitaxel therapeutic drug monitoring - international association of therapeutic drug monitoring and clinical toxicology recommendations","volume":"202","author":"Hertz","year":"2024","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.annonc.2026.03.002_bib17","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.002_bib18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","article-title":"Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial","volume":"17","author":"Takashima","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.03.002_bib19","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.002_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.21.02953","article-title":"Open-label, randomized, multicenter, phase III study comparing oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer","volume":"41","author":"Rugo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.03.002_bib21","article-title":"Abstract GS4-01: Results from CONTESSA: a phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane","volume":"81","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2026.03.002_bib22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clinthera.2014.12.009","article-title":"Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation","volume":"37","author":"Lim","year":"2015","journal-title":"Clin Ther"},{"issue":"2 Spec. No.","key":"10.1016\/j.annonc.2026.03.002_bib23","first-page":"SP46","article-title":"Cost of home vs clinic administration of paclitaxel in metastatic breast cancer","volume":"27","author":"Sharma","year":"2021","journal-title":"Am J Manag Care"},{"issue":"11","key":"10.1016\/j.annonc.2026.03.002_bib24","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/JTO.0b013e31822722b6","article-title":"Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials","volume":"6","author":"Hasegawa","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2026.03.002_bib25","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-15-0586","article-title":"Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199","volume":"21","author":"Schneider","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:42:09Z","timestamp":1785876129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0923753426001006"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.03.002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}